NCT07206290View on ClinicalTrials.gov

Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 2, 2026

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Chronic Kidney Disease

Interventions

DRUG

Survodutide (BI 456906)

0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c. weekly

DRUG

Placebo

Placebo matching survodutide

All Listed Sponsors

lead

University Medical Center Groningen

OTHER